Evidence for both in vivo and in vitro interaction between vigabatrin and alanine transaminase

British Journal of Clinical Pharmacology

Volumn 43, Issue 2, 1997, Pages 163-168

  Richens, Alan ^a,b   McEwan, Jean R ^c   Deybach, Jean C ^d   Mumford, John P ^e  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^c HÔPITAL LOUIS MOURIER   (France)

^d Marion Menell don'Research Centre   (United Kingdom)

^e Pharmaceutical Medicine   (United Kingdom)

Author keywords

Alanine transaminase; Anti epilepsy drugs; Aspartate transaminase; GABA aminotransaminase; Interaction; Vigabatrin

Indexed keywords

4 AMINOBUTYRIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; VIGABATRIN;

ADULT; ARTICLE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; EPILEPSY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0031045218     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.05295.x     Document Type: Article

References (18)

1. Elliott KA, van Gelder NM. Occlusion and metabolism of GADA by brain tissue. J Neurochem 1958; 3: 28-40.
2. Bey P. Mechanism-based enzyme inhibitors as an approach to drug design. In Enzymes as Targets for Dmg Design, eds Palfrewyman MG, McCann PP, Lovenberg W, Temple JR Jr, Sjoedsma A. San Diego: Academic Press Inc., 1989; 59-83.
3. Jung MJ, Lippert B, Metcalf BW, Schlechter PJ, Bohlen P, Sjoedsma A. The effect of 4-amino-hex-5-enoic acid (gamma-acetylenic GABA, gamma-ethynyl GABA) a catalytic inhibitor of GABA transaminase, on brain GABA metabolism in vwo. J Neurodiem 1977; 28: 717-723.
4. Jung MJ, Lippert B, Metcalf BW, Bohlen P, Schlechter PJ. Gamma-vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neiirochem 1977; 29: 797-802.
5. Ben-Menachem E, Hamberger A, Mumford JP. Effect of long term vigabatrin therapy on GABA and other amino acid concentrations in the central nervous system - a case study. Epilepsy Res 1993; 16: 241-243.
6. Haegele KD, Schlechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Tlier 1986; 40: 581-586.
7. Löscher W, Schmidt D. Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 1988; 2: 145-181.
8. Rimmer E, Richens A. Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet 1984; i: 189-190.
9. Gram L, Lyon BB, Dam M. Gamma vinyl GABA: a single blind trial in patients with epilepsy. Acta Neural Scand 1983; 68: 34-39.
10. Browne TR, Mattson RH, Penry JK, et al. A multicentre study of vigabatrin for drug-resistant epilepsy. Br J Clin Pharmacol 1989; 27(suppl 1): 95S-100S.
11. Mumford JP, Dam M. Meta-analysis of European placebo controlled studies of vigabatrin in drug resistant epilepsy. Br J Clin Pharmacol 1989; 27(suppl 1): 101S-107S.
12. Grant SM, Heel RC. Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Dmgs 1991; 41: 889-926.
13. Hulsman J. The influence of vigabatrin on ALA-T activity measurements. Clin Client 1993; 39: 1142 (Abstract).
14. Lippert B, Metcalf BW, Jung MJ, Casera P. 4-Amino-hex5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. Eur J Biochein 1977; 74: 441-445.
15. Foletti GB, Delisle M-C, Bachmann C. Reduction of plasma alanine aminotransferase during vigabatrin treatment. Epilepsia 1995; 36: 804-809.
16. Chiron C, Dulac O, Beaumont D, Palacios L, Pajot N, Mumford J. Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neural 1991; 6(suppl 2): S52-S59.
17. Chiron C, Dulac O, Luna D, et al. Tolerability of vigabatrin in children Vigabatrin in Europe. Luxembourg, November 21-23, 1991.
18. Remy C, Beaumont D. Efficacy and safety of vigabatrin in long-term treatment of refractory epilepsy. BrJ Clin Pharmacol 1989; 27(suppl 1): 125S-129S.